return to news
  1. What Happens To Indian IT If AI Development Actually Slows

Market News

What Happens To Indian IT If AI Development Actually Slows

Upstox

11m 54s | Updated on September 16, 2026, 13:18 IST

SUMMARY

In this episode of Markets Today, we decode why some AI leaders are calling for a slowdown in AI development and what it could mean for struggling Indian IT stocks, how stricter QR code based medicine traceability rules could benefit large pharma companies like Sun Pharma, Dr Reddy's and Cipla, and why NSE's upcoming IPO could reshape India's unlisted share market by removing its biggest attraction.

In this episode of Markets Today — AI industry CEOs call for a development slowdown, and whether it could give Indian IT stocks a lifeline; new traceability rules to curb fake medicines could hand organised pharma giants a competitive edge; and NSE's mega IPO could end India's booming unlisted share market's biggest attraction.

AI's Slowdown Call — Real Concern Or Convenient Shield? Anthropic's Dario Amodei is calling for AI development to slow down, even as Big Tech plans ~$800 billion in 2026 AI infra spend. Nifty IT is down ~37% from its record high — a genuine slowdown could buy Indian IT time.

Fake Medicine Crackdown Could Favour Big Pharma India is expanding QR-code traceability to cover vaccines and anti-cancer medicines by July 2027. Potential beneficiaries: Sun Pharma, Dr Reddy's, Cipla, Lupin and Zydus, given their established distribution networks.

NSE's IPO Could Reshape The Unlisted Share Market NSE shares made up roughly half of all unlisted-share trading since 2016. Once listed, investors no longer need unlisted platforms — pushing attention toward names like Sterlite Electric and Garuda Aerospace.

About The Author

Upstox
Upstox News Desk is a team of journalists who passionately cover stock markets, economy, commodities, latest business trends, and personal finance.

Next Story